SCHEMBL15944158

SCHEMBL15944158

Cc1ccc2ncn(C3CN(C)C3)c2c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 3/20 0.40
GLRA3 O75311 1/20 0.39
GLRB P48167 1/20 0.39
DRD2 P14416 1/20 0.39
SLC6A4 P31645 1/20 0.39
FGFR1 P11362 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.36
HRH4 Q9H3N8 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
MCHR1 Q99705 2/20 0.35
PRKCI P41743 1/20 0.35
TNF P01375 1/20 0.35
TLR8 Q9NR97 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
ATM Q13315 1/20 0.34
IDO1 P14902 1/20 0.34
HSD17B10 Q99714 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15944159 0.90 DRD2 (0.45) PRMT5DRD2SLC6A4FGFR1IRAK4
SCHEMBL18136608 0.87 DRD2 (0.40) PRMT5DRD2SLC6A4MCHR1ATM
SCHEMBL4743122 0.85 DRD2 (0.44) DRD2SLC6A4FGFR1IRAK4PRKCI
SCHEMBL15344990 0.85 DRD2 (0.49) PRMT5DRD2SLC6A4HRH4HRH3
SCHEMBL15823728 0.83 FABP4 (0.40) PRMT5GLRA3GLRBDRD2SLC6A4
SCHEMBL18136684 0.83 GAA (0.50) DRD2SLC6A4NPC1ATMHSD17B10
SCHEMBL17678351 0.83 GAA (0.47) DRD2SLC6A4FGFR1NPC1ATM
SCHEMBL15833610 0.82 HCAR1 (0.50) PRMT5DRD2SLC6A4IRAK4HSD17B10
SCHEMBL15943763 0.82 PRMT5 (0.39) PRMT5GLRA3GLRBDRD2SLC6A4
SCHEMBL15833603 0.81 PRKCI (0.51) PRMT5DRD2SLC6A4FGFR1IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021139775-A1 PYRIDONE COMPOUND AND APPLICATION 江苏先声药业有限公司 2021-07-15 WO disclosed
US-9777008-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2017-10-03 US disclosed
US-20170114061-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-04-27 US disclosed
US-20160214985-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-07-28 US disclosed
US-9388173-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2016-07-12 US disclosed
US-20150133427-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-05-14 US disclosed
US-8906900-B2 PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2014-12-09 US disclosed
US-20140228343-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133427-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 PRMT5 1/4885GLRA3 2789/4885GLRB 2792/4885
US-20160214985-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 PRMT5 1/4885GLRA3 2688/4885GLRB 2858/4885
US-20140228343-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 PRMT5 1/4885GLRA3 2789/4885GLRB 2792/4885
US-20170114061-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 PRMT5 1/4885GLRA3 2789/4885GLRB 2792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.